Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital

Table 1

Profile of patients, baseline characteristics. N = 248.

Factor	Number ()	Factor	Mean ± SD; Median (IQR)
Gender		Age (years)	5.3 ± 3.4
Male	134 (54.0%)		5 (2-7)
Female	114 (46.0%)
Treatment		Weight (kg)	18.0 ± 12.3
Vancomycin alone	36 (14.5%)		16.0 (9.8-22.0)
Vancomycin and PTZ	62 (25.0%)
Vancomycin plus Ceftazidime	99 (39.9%)
Vancomycin plus Ceftriaxone	51 (20.6%)	Height (cm)	100.1 ± 28.0
			104 (79-119)
Indication of Antibiotics
Empirical	79 (31.9%)	Creatinine (mg/dL)	0.45 ± 0.1
Pneumonia	37 (14.9%)		0.44 (0.38-0.5)
Fever	33 (13.3%)
URTI	23 (9.3%)
Sepsis	17 (6.9%)	BUN (mg/dL)	10.1 ± 5.3
Other	59 (23.7%)		8.7 (6.2-13.7)
Underlying conditions
History of G6PD deficiency	6 (2.4%)	WBC (x 10^9/L)	10.9 ± 7.3
Trauma	5 (2.0%)		10.0 (5.4-15.0)
GERD	14 (5.6%)
Cerebral Palsy	9 (3.6%)	LOS Before Therapy (days)	6.7 ± 19.9
Sickle Cell Disease	15 (6.0%)		0 (0-4)
Congenital Heart Disease	31 (12.5%)
Asthma	46 (18.5%)
Seizures	36 (14.5%)	Use of concomitant nephrotoxins	76 (30.6%)
Diabetes	2 (0.8%)
History of Malignancy	20 (8.1%)

Other: febrile neutropenia, meningitis, UTI, bacteremia, skin infection, and trauma.
Aminoglycoside, furosemide, amphotericin B, colistin, ACEIs, ARBs, NSAID, tacrolimus, acyclovir, and cyclosporine.
URTI: upper respiratory tract infection, G5PD: Glucose-6-Phosphate Dehydrogenase, GERD: gastroesophageal reflux disease, BUN: blood urea nitrogen, and LOS: length of stay.